

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KUANGCHI SCIENCE LIMITED

光啟科學有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 439)

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board announces that with effect from 8 May 2023:

- (1) Dr. Deng Ke has resigned as an Independent Non-executive Director, a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company; and
- (2) Dr. Wu Zhili has been appointed as an Independent Non-executive Director, a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company.

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of KuangChi Science Limited (the “**Company**”) announces that Dr. Deng Ke (“**Dr. Deng**”) has resigned as an Independent Non-executive Director, and as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company with effect from 8 May 2023, due to his wish to focus on other business engagement. Dr. Deng has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company in connection with his resignation.

Following the resignation of Dr. Deng, Dr. Wu Zhili (“**Dr. Wu**”) has been appointed as an Independent Non-executive Director of the Company to fill the casual vacancy to the Board with effect from 8 May 2023.

The biographical details of Dr. Wu are set out below:

Dr. Wu Zhili (“**Dr. Wu**”), aged 42, graduated from Hong Kong Baptist University in 2002, majoring in computer science and obtained a bachelor’s degree. He has been studying in Hong Kong Baptist University thereafter and obtained a master’s degree and a doctoral degree in 2004 and 2008, respectively. Dr. Wu engaged in post-doctoral research at Hong Kong Baptist University from 2008 to 2009, while he engaged in post-doctoral research at the University of Leeds in the United Kingdom from 2009 to 2010. Dr. Wu has served as a senior researcher in Ericsson Research Institute (愛立信研究院) and has worked as the chief AI officer and data officer in various companies. Afterwards, since 2017, Mr. Wu founded Shenzhen Yiyuan Intelligent Technology Co., Ltd. (深圳市宜遠智能科技有限公司) (“**Yiyuan Intelligent**”). Yiyuan Intelligent focuses on the application of AI technology on the product development and expansion in the field of skin image segmentation and is actively expanding the feasibility of implementing AI-assisted dermatosis diagnosis and treatment in hospitals.

In addition to serving as visiting professor and external hire lecturer, Dr. Wu has published numerous articles in relation to the artificial intelligence sector, with an aim to contribute to the technology and research of artificial intelligence.

Save as disclosed above, Dr. Wu did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

By an appointment letter entered into with the Company on 8 May 2023, Dr. Wu shall serve as an Independent Non-executive Director for a term of three years but he will be subject to re-election at the next general meeting of the Company in accordance with the bye-laws of the Company. The director’s fee payable to him is fixed at the rate of HK\$250,000 per annum, which was reviewed by the Remuneration Committee of the Company and determined by the Board with reference to his experience, duties and responsibilities in the Company as well as the current market rate.

As at the date of this announcement, Dr. Wu (i) does not hold any other positions in the Company or any of its subsidiaries; (ii) does not have any relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; and (iii) is not interested in any securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 Law of Hong Kong).

Dr. Wu has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Save as disclosed above, the Board is not aware of any other matters concerning Dr. Wu’s appointment that need to be brought to the attention of the shareholders of the Company nor any information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board further announces that following the resignation of Dr. Deng as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company and Dr. Wu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company with effect from 8 May 2023.

The Board would like to take this opportunity to express its gratitude to Dr. Deng for his valuable contributions to the Group during his tenure of service and also express its warm welcome to Dr. Wu for joining the Company.

By Order of the Board
KuangChi Science Limited
Mr. Cheng Chi Chung Kevin
Company Secretary

Hong Kong, 8 May 2023

As at the date of this announcement, the board of directors comprises four executive directors, namely Dr. Liu Ruopeng, Dr. Luan Lin, Dr. Zhang Yangyang and Dr. Ji Chunlin; one non-executive director namely Mr. Li Chiu Ho; and three independent non-executive directors, namely, Dr. Wong Kai Kit, Mr. Choi Wing Koon and Dr. Wu Zhili.